Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting.

ABSTRACT:

Background

To report on the short-term outcome of intravitreal brolucizumab in patients with neovascular age-related macular degeneration (nAMD).

Methods

This is a prospective, interventional, monocentric study on 10 eyes of 10 patients with a treatment-naïve neovascular AMD. Patients were treated according to the HAWK and HARRIER trials. After loading with 3 monthly injections, eyes received an injection 12 weeks after the upload (q12w) or were adjusted to an 8 week interval (q8w), if disease activity was present 8 weeks after the upload. Main outcome measures were the change in central retinal thickness (CRT) assessed by spectral domain optical coherence tomography (SD-OCT), the change in macular neovascularization (MNV) size on optical coherence tomography angiography (OC

SUBMITTER: Rubsam A 

PROVIDER: S-EPMC8975682 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature